The Effect of Rosuvastatin on Prevention of Contrast-Induced Acute Kidney Injury in Patients with Chronic Kidney Disease

Document Type : Original Article (s)

Authors

1 Assistant professor, Department of Nephrology, School of Medicine AND Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant professor, Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Contrast-induced acute kidney injury (CI-AKI) is an important issue in patients who are candidate for using contrast media in order to do diagnostic and therapeutic imagining. This study aimed to investigate the effect of rosuvastatin on the development of contrast-induced acute kidney injury in patients with chronic kidney disease performing computed tomography (CT) scan with contrast media.Methods: In this clinical trial study, 402 patients with chronic kidney disease who underwent CT scan with contrast in Alzahra hospital, Isfahan, Iran, during the years 2018-2019 were studied. Patients were divided into two groups, patients in the first group received 20 mg rosuvastatin 24 hours prior to CT scan and 10 mg rosuvastatin tablets daily for two consecutive days. The second group received the placebo.Findings: There was a significant difference in creatinine and glomerular filtration rate (eGFR) after CT scan (P < 0.050). The mean of creatinine was lower, and the mean of eGFR was higher in the intervention group than placebo after the intervention (P < 0.050). The frequency of contrast-induced acute kidney injury in the intervention group was 1%, and in the placebo group was 4% (P = 0.059).Conclusion: Rosuvastatin can reduce the risk of contrast-induced acute kidney injury after using contrast media, including increase in creatinine, and decrease in eGFR.

Keywords

References

  1. Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med 2001; 2(Suppl 1): S14-S18.
  2. Massry SG, Glassock RJ. Massry and Glassock's textbook of nephrology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 950-3.
  3. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11(1): 177-82.
  4. Porter GA. Contrast-associated nephropathy. Am J Cardiol 1989; 64(9): 22E-6E.
  5. Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med 2004; 350(24): 2438-40.
  6. Haghdoost A, Mirzazadeh A. Familial Aggregation of coronary heart disease risk factors in Kerman province. Iran J Epidemiol 2006; 2(1-2): 59-64. [In Persian].
  7. Tepel M. Acetylcysteine for the prevention of radiocontrast-induced nephropathy. Minerva Cardioangiol 2003; 51(5): 525-30.
  8. Billinger M, Hess OM, Meier B. Prevention of contrast-induced renal dysfunction by N-acetylcysteine: Truth or myth? Eur Heart J 2004; 25(3): 188-9.
  9. Sharfuddin AA, Weisbord SD, Palevsky PM, Molitoris BA. Acute kidney injury. In: Skorecki K, Chertow G, Marsden P, Taal M, Yu A, editors. Brenner and Rector's the kidney. 10th ed. Philadelphia, PA: Elsevier; 2015.
  10. Ozkok S, Ozkok A. Contrast-induced acute kidney injury: A review of practical points. World J Nephrol 2017; 6(3): 86-99.
  11. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014; 63(1): 62-70.
  12. Khanal S. Validation of the J-Chronic Total Occlusion Score for chronic total occlusion percutaneous coronary intervention in an independent contemporary cohort. Indian Heart J 2014; 66(3): 386-7.
  13. Yang Y, Wu YX, Hu YZ. Rosuvastatin treatment for preventing contrast-induced acute kidney injury after cardiac catheterization: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015; 94(30): e1226.
  14. Qiao B, Deng J, Li Y, Wang X, Han Y. Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J Clin Exp Med 2015; 8(2): 2342-9.
  15. Singh N, Lee JZ, Huang JJ, Low SW, Howe C, Pandit A, et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: Systematic review and meta-analysis. Open Heart 2014; 1(1): e000127.
  16. Forghani MS, Fathizade K, Vahedi S, Ataei S, Roshani D. Does high-dose lovastatin therapy diminish the risk of iodinated contrast induced acute kidney injury? A double-blind placebo-controlled clinical trial. J Renal Inj Prev 2018; 7(2): 94-7.
  17. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. Am J Med 2014; 127(10): 987-1000.
Journal of Isfahan Medical School
Volume 38, Issue 589 - Serial Number 589
July and August 2020
Pages 628-633

Files

History

  • Receive Date: 24 August 2020
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics